Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634086 | 0.79 | OPRK1 (0.50) | OPRK1ACHEDRD3DRD2NFKB1 | |
| SCHEMBL4794047 | 0.79 | OPRK1 (0.53) | OPRK1ACHEMCHR1HTR2CKCNH2 | |
| SCHEMBL4779647 | 0.77 | DRD3 (0.42) | MCHR1HTR2CKCNH2DRD3DRD2 | |
| SCHEMBL9452833 | 0.72 | OPRK1 (0.55) | OPRK1DRD3DRD2NFKB1THPO | |
| SCHEMBL4792233 | 0.72 | DRD3 (0.44) | MCHR1HTR2CKCNH2DRD3DRD2 | |
| SCHEMBL5663565 | 0.72 | OPRK1 (0.62) | OPRK1DRD3DRD2NFKB1THPO | |
| SCHEMBL5663561 | 0.72 | OPRK1 (0.62) | OPRK1DRD3DRD2NFKB1THPO | |
| SCHEMBL5935171 | 0.71 | DRD3 (0.42) | MCHR1HTR2CKCNH2DRD3DRD2 | |
| SCHEMBL4725409 | 0.71 | MCHR1 (0.52) | MCHR1HTR2CKCNH2DRD3DRD2 | |
| SCHEMBL4793677 | 0.71 | MCHR1 (0.52) | MCHR1HTR2CKCNH2DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | claimed |
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | OPRK1 90/4885ACHE 2533/4885MCHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.